HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults.

Abstract
In a cooperative randomized control study of immunotherapy with bestatin in combination with chemotherapy in adults with acute nonlymphocytic leukemia (ANLL), 101 patients (48 in the bestatin group and 53 in the control group) out of 115 patients registered were evaluated as eligible. The bestatin group achieved a statistically significant prolongation of survival compared with the control group in overall ANLL and acute myelogenous leukemia. In the analysis of patient age, the bestatin group achieved a statistically significant prolongation of both the remission duration and survival in patients aged 50 to 65 years, while the differences were not significant in the 15 to 49 age group. The bestatin group tended to achieve a higher rate of reinduction of remission in patients who had recurrence of leukemia. Side effects developed in only 5 (9.6%) of 52 patients treated with bestatin. None of these side effects were particularly serious in nature. It is concluded that bestatin is useful for prolongation of survival of adult patients with ANLL, making for a longer remission duration especially in elderly patients and with few side effects.
AuthorsK Ota, S Kurita, K Yamada, T Masaoka, Y Uzuka, N Ogawa
JournalCancer immunology, immunotherapy : CII (Cancer Immunol Immunother) Vol. 23 Issue 1 Pg. 5-10 ( 1986) ISSN: 0340-7004 [Print] Germany
PMID3533256 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Adjuvants, Immunologic
  • Leucine
  • ubenimex
Topics
  • Acute Disease
  • Adjuvants, Immunologic (administration & dosage, adverse effects, therapeutic use)
  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Clinical Trials as Topic
  • Female
  • Humans
  • Leucine (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
  • Leukemia (mortality, pathology, therapy)
  • Leukemia, Myeloid (therapy)
  • Male
  • Middle Aged
  • Random Allocation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: